Abstract: Described herein are variant, novel cannabinoid synthases, nucleic acids encoding same, and various uses thereof.

Abstract: Described herein are variant, novel cannabinoid synthases, nucleic acids encoding same, and various uses thereof.

Abstract: The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant prenyltransferase enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to the wild type prenyltransferase. The disclosure also provides methods of preparing such recombinant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.

Abstract: The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant mutant ORF2 enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to WT ORF2. The disclosure also provides methods of preparing such ORF2 mutant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.

Abstract: Described herein are variant, novel cannabinoid synthases, nucleic acids encoding same, and various uses thereof.

Abstract: The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant mutant ORF2 enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to WT ORF2. The disclosure also provides methods of preparing such ORF2 mutant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.

Abstract: The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant mutant ORF2 enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to WT ORF2. The disclosure also provides methods of preparing such ORF2 mutant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: The present disclosure relates to methods of expressing therapeutic proteins in photosynthetic organisms and the therapeutic proteins produced by the methods. The therapeutic proteins include high-mobility group box 1 (HMGB1) protein, fibronectin domain (10) (10FN3), fibronectin domain (14) (14FN3), interferon beta (IFN?), proinsulin and vascular endothelial growth factor (VEGF). The photosynthetic organisms include prokaryotes such as cyanobacteria and eukaryotes such as alga and plants. Transformation of eukaryotes is preferably the plastid genome, more preferably the chloroplast genome.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: The present disclosure provides novel proteins that when over expressed in algae result in an increase or change in fatty acid and/or glycerol lipid production and/or accumulation, without a substantial decrease in the growth rate of the alga or the break down of algal components, such as chlorophyll. The present disclosure also describes methods of using the novel proteins to increase or change the production and/or accumulation of fatty acids and/or glycerol lipids in algae. In addition, these proteins are useful tools in obtaining information about the fatty acid and triacyglyceride (TAG) synthetic pathways in algae.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: The present disclosure relates to bioengineering approaches for producing biofuel and, in particular, to the use of a C1 metabolizing microorganism reactor system for converting C1 substrates, such as methane or methanol, into biomass and subsequently into biofuels, bioplastics, or the like.

Abstract: The present invention provides compositions and methods for producing flocculation moieties in photosynthetic organisms. The photosynthetic organisms are genetically modified to effect production, secretion, or both, of the flocculation moieties. Also provided are methods of flocculating organisms.

Abstract: This disclosure provides methods of designing and generating polypeptide variants that have altered properties compared to a parent polypeptide. The present disclosure provides methods of generating polypeptide variants, for example, variant isoprenoid synthases and/or variant prenyl transferases that have at least one desired property not present in the parent polypeptide. The present disclosure further provides polypeptides and polynucleotides encoding variant polypeptides, as well as vectors and host cells comprising the polynucleotides that encode the variant polypeptides. In other embodiments, the present disclosure provides methods of using the variant polypeptides to generate useful products, such as isoprenoid compounds and/or isoprenoid products.